Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
367 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03930953 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | active not recruiting | Phase 1 / Phase 2 | 438 | CelgeneINDUSTRY | 15 | Feb 19, 2026 | clinicaltrials |
| NCT03779113 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | terminated | Phase 1 | 69 | HutchmedINDUSTRY | 7 | Feb 18, 2026 |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | terminated | Phase 1 / Phase 2 | 200 | CelgeneINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma(Spencer) | terminated | Phase 1 / Phase 2 | 70 | EnteromeINDUSTRY | 8 | Jan 30, 2026 | clinicaltrials |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | GenmabINDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT05830084 | Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma(REGO-INTER-EWI) | active not recruiting | Phase 1 | 23 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Jan 6, 2026 | clinicaltrials |
| NCT01695005 | A Study of LY3039478 in Participants With Advanced Cancer | completed | Phase 1 | 247 | Eli Lilly and CompanyINDUSTRY | 6 | Dec 26, 2025 | clinicaltrials |
| NCT06232408 | LIONS (PLK4 Inhibitor in Advanced Solid Tumors) | terminated | Phase 1 | 29 | Repare TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)(OXTEND-01) | terminated | Phase 1 | 19 | Debiopharm International SAINDUSTRY | 8 | Nov 17, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT04497116 | Study of RP-3500, Camonsertib, in Advanced Solid Tumors(TRESR) | completed | Phase 1 / Phase 2 | 276 | Repare TherapeuticsINDUSTRY | 4 | Oct 21, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT03522142 | A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies | terminated | Phase 1 | 83 | Incyte CorporationINDUSTRY | 5 | Oct 9, 2025 | clinicaltrials |
| NCT05216835 | Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 1 | 45 | AstraZenecaINDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT06204991 | To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma(ADP-TILIL7) | recruiting | Phase 1 | 10 | Inge Marie SvaneOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT03039114 | Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) | completed | Phase 1 | 26 | Incyte CorporationINDUSTRY | 6 | Aug 21, 2025 | clinicaltrials |
| NCT04876092 | A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL | completed | Phase 1 | 45 | Janssen Research & Development, LLCINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | terminated | Phase 1 / Phase 2 | 6 | Inge Marie SvaneOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04217473 | TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma(TUNINTIL) | completed | Phase 1 | 17 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT04904185 | ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma | terminated | Phase 1 | 8 | Inge Marie SvaneOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04826003 | Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment | completed | Phase 1 | 54 | Hoffmann-La RocheINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT01226316 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | completed | Phase 1 | 285 | AstraZenecaINDUSTRY | 10 | Jun 29, 2025 | clinicaltrials |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children(SCOUT) | active not recruiting | Phase 1 / Phase 2 | 154 | BayerINDUSTRY | 21 | Jun 22, 2025 | clinicaltrials |
| NCT06087289 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(KANDOVA) | completed | Phase 1 / Phase 2 | 18 | Novakand Pharma ABINDUSTRY | 3 | Jun 8, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT02519452 | A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 6 | May 23, 2025 | clinicaltrials |
| NCT05187624 | A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma | completed | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | May 22, 2025 | clinicaltrials |
| NCT04642365 | A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. | terminated | Phase 1 | 49 | Hoffmann-La RocheINDUSTRY | 6 | May 21, 2025 | clinicaltrials |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | terminated | Phase 1 | 54 | Kinnate BiopharmaINDUSTRY | 6 | May 7, 2025 | clinicaltrials |
| NCT04209465 | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.(MasterKey-01) | terminated | Phase 1 | 91 | Black Diamond Therapeutics, Inc.INDUSTRY | 4 | Apr 17, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04236414 | Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 6 | Apr 4, 2025 | clinicaltrials |
| NCT04247165 | Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.(LAPTOP) | completed | Phase 1 / Phase 2 | 55 | Herlev HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05619744 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | completed | Phase 1 | 41 | Hoffmann-La RocheINDUSTRY | 5 | Mar 10, 2025 | clinicaltrials |
| NCT03047928 | Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 48 | Inge Marie SvaneOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05243342 | A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 18 | Genentech, Inc.INDUSTRY | 4 | Feb 17, 2025 | clinicaltrials |
| NCT06783270 | T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma(CRISPR-TIL) | recruiting | Phase 1 | 10 | Inge Marie SvaneOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT01928394 | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 1,163 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 27, 2024 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials